Angiosarcoma
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Angiosarcoma

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Angiosarcoma Local Doctors?
Chandrajit P. Raut
Elite in Angiosarcoma
Surgical Oncology
Elite in Angiosarcoma
Surgical Oncology

Brigham And Women's Hospital, Division Of Surgical Oncology

45 Francis Street, Asb2-3, 
Boston, MA 
Languages Spoken:
English

Dr. Raut is the Chief of the Division of Surgical Oncology and the inaugural Distinguished Chair for Cancer Care at Brigham and Women's Hospital. He received a BA and BS from Stanford University, MSc from University of Oxford, and MD from Harvard Medical School, where he is also a Professor of Surgery. He completed his residency in general surgery at Massachusetts General Hospital and fellowship in surgical oncology at MD Anderson Cancer Center. Dr. Raut specializes in the multidisciplinary care of patients with soft tissue sarcoma and serves as the Surgery Director for the Center for Sarcoma and Bone Oncology at Dana-Farber Brigham Cancer Center (DFBCC). His research focuses on multimodal strategies to reduce rates of local recurrence for patients with sarcoma. Dr. Raut is rated as an Elite provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Liposarcoma, Nephrectomy, and Pancreaticoduodenectomy.

Richard F. Riedel
Elite in Angiosarcoma
Elite in Angiosarcoma

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
Experience:
26+ years
Languages Spoken:
English
Offers Telehealth

I am a medical oncologist who focuses on bone and soft tissue cancers called sarcomas. I love spending time with my patients. They often have a sense of awareness about their condition that’s truly unique and rewarding. I partner with each patient so they know the full set of options available for treatment and can make an informed decision about the approach that is best for them. I’ve wanted to pursue medicine for as long as I can remember. I find cancer fascinating because of its ability to evade the immune system. The body fails to recognize cancer as being foreign. When I am not at work, I love spending time with my family and enjoy long distance running. Dr. Riedel is rated as an Elite provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Desmoid Tumor, and Angiosarcoma.

 
 
 
 
Learn about our expert tiers
Learn More
Pamela E. Kaiser
Distinguished in Angiosarcoma
Hematology | Oncology
Distinguished in Angiosarcoma
Hematology | Oncology

Advocate Lutheran General Cancer Institute

1700 Luther Ln 1st & 2nd Fl, 
Park Ridge, IL 
Languages Spoken:
English

Pamela Kaiser is a Hematologist and an Oncologist in Park Ridge, Illinois. Dr. Kaiser is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Angiosarcoma, Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Endoscopy.

What are the latest Angiosarcoma Clinical Trials?
Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma

Summary: This is a single arm, open-label phase II study to assess the efficacy of single agent pembrolizumab for the treatment of advanced cutaneous sarcomas. Adult patients ≥18 years old who have been diagnosed with an advanced cutaneous sarcoma without regard to race, ethnicity, and/or gender. Approximately N=17 patients are planned to be enrolled. Pembrolizumab 200 mg will be administered as 30-minute ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
An Open-Label, Multicenter, Phase 2 Study With Safety Lead-In of Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab in Patients With Angiosarcoma

Summary: This is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrolizumab for treating participants with angiosarcoma. This is the first study evaluating this novel combination in participants with advanced angiosarcoma who have progressed after prior immunotherapy.